Evaluation of nucleoside reverse transcriptase inhibitor dosing during continuous veno-venous hemofiltration
- 208 Downloads
Background Unpredictable drug concentrations may lead to suboptimal exposure to nucleoside reverse transcriptase inhibitors (NRTIs) due to inadequate doses administered during continuous veno-venous hemofiltration (CVVH), which in turn may lead to decreased antiretroviral efficacy and possibly further HIV disease progression. Objective To compare administered doses of NRTIs to calculated doses of NRTIs to evaluate if patients were expected to have a favorable pharmacokinetic exposure profile while receiving CVVH. Methods The NRTI dose was compared to a table of recommendations based on a mathematical formula that estimates the amount of drug expected to be removed during CVVH. Results Twelve patients were on 27 NRTIs. Eleven (41%) NRTI doses were expected to provide a favorable pharmacokinetic profile based on pharmacokinetic mathematical calculations. Conclusion The majority of NRTIs were potentially not optimally dosed based on proposed pharmacokinetic calculations.
KeywordsContinuous veno-vous hemofiltration HIV Nucleoside reverse transcriptase inhibitor Pharmacokinetics NRTIs
This study was funded in part by a student research grant from Midwestern University Chicago College of Pharmacy, Downers Grove, IL.
Conflicts of interest
Milena M. McLaughlin, Inela Masic, Lana Gerzenshtein declare that they have no conflicts of interest.
- 4.Gupta SK, Eustace JA, Winston JA, Boydstun II, Ahuja TS, Rodriguez RA, et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2005;40:1559–85.CrossRefPubMedGoogle Scholar
- 5.Fabbiani M, Di Giambenedetto S, Bracciale L, Bacarelli A, Ragazzoni E, Cauda R, et al. Pharmacokinetic variability of antiretroviral drugs and correlation with virological outcome: 2 years of experience in routine clinical practice. J Antimicrob Chemother. 2009;64:109–17.CrossRefPubMedGoogle Scholar
- 11.Panel on antiretroviral guidelines for adults and adolescents. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents. http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf. Accessed 27 July 2016.